Open AccessHydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial
Author(s) -
Samuel M. Brown,
Ithan D. Peltan,
Naresh Kumar,
Lindsay Leither,
Brandon Webb,
Nathan Starr,
Colin K. Grissom,
Whitney R. Buckel,
Rajendu Srivastava,
Alison Butler,
Danielle Groat,
Benjamin Haaland,
Ying Jin,
Estelle S. Harris,
Stacy A. Johnson,
Robert Paine,
Tom Greene
Publication year - 2021
Publication title -
annals of the american thoracic society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 114
eISSN - 2329-6933
pISSN - 2325-6621
DOI - 10.1513/annalsats.202008-940oc
Subject(s) - hydroxychloroquine , azithromycin , medicine , odds ratio , randomized controlled trial , clinical endpoint , placebo , clinical trial , covid-19 , pathology , alternative medicine , disease , infectious disease (medical specialty) , microbiology and biotechnology , biology , antibiotics
The COVID-19 pandemic struck an immunologically naïve, globally interconnected population. In the face of a new infectious agent causing acute respiratory failure for which there were no known effective therapies, rapid, often pragmatic trials were necessary to evaluate potential treatments, frequently starting with medications that are already marketed for other indications. Early in the pandemic, hydroxychloroquine and azithromycin were two such candidates.